Opinion|Videos|December 29, 2023
Clinical Data on the Approved JAK Inhibitors for Treatment of Myelofibrosis
Author(s)Christine Cooper, RN, BSN, Aaron Gerds, MD, MS
An expert discusses the four FDA-approved JAK inhibitors for myelofibrosis - ruxolitinib, fedratinib, pacritinib, and momelotinib.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on CURE
1
New Combination Treatment Approach Studied in Pancreatic Cancer
2
Why Is Lung Health Key to Survivorship After Cancer Treatment?
3
U.S. Soccer Legend Kasey Keller Reveals Lymphoma Journey
4
FDA Updates Safety Warnings for Common Chemotherapy Drugs
5